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ABSTRACT 
 
The hepatitis B X (HBx) protein is a crucial component in hepatitis B virus (HBV) infection in vivo 
and has been implicated in hepatocellular carcinoma. In this study, we aimed to detect and characterize 
peripheral HBx-specific T cells in chronically infected patients at the inactive carrier state of the 
disease. HBx-specific IFN--secreting T cells were found in 36 of 52 patients (69%) and 78% (28/36) 
of responding patients had T cells targeting epitopes in the carboxy-terminal part of HBx. IL-10 
secretion following the stimulation of T cells with HBx-derived peptides was weak or undetectable. 
IFN--secreting T cells recognized a previously unknown immunodominant CD4+ T-cell epitope, 
HBx 126-140 (EIRLKVFVLGGCRHK), in 86% (24/28) of patients. This peptide bound several HLA-
DR molecules (HLA-DRB1*0101, HLA-DRB1*0401, HLA-DRB1*1301 and HLA-DRB5*0101). Its 
coding sequence overlaps a domain of the HBV genome encompassing the basic core promoter (BCP) 
region. Taking into account the selection of viral core promoter mutants during HBV infection, we 
found that HBV variants with BCP mutations were present in patient sera. We further demonstrated 
that these viral mutant sequences activated T cells specific for the immunodominant epitope only 
weakly, if at all. This is the first study linking BCP mutations and HBx-specific T-cell responses. 
Therefore, wild type and variant peptides may represent potentially tools for monitoring the HBV-
specific T-cell responses involved in sequence evolution during disease progression. Finally, the 
degenerate HLA-DR binding of this promiscuous, immunodominant peptide would make it a valuable 
component of vaccines for protecting large and ethnically diverse patient populations.  
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INTRODUCTION  
 
An effective vaccine against hepatitis B virus (HBV) infection has been available for more than two 
decades, but 400 million people —more than 5% of the world's population — are chronically infected 
with HBV, and  more than 1 million people die each year from HBV-related liver cirrhosis and 
hepatocellular carcinoma (HCC) (1, 2). 
The hepatitis B X (HBx) protein is a key element in HBV infection in vivo and has been implicated in 
HCC development. HBx is well conserved among mammalian hepadnaviruses and is produced very 
early after infection and throughout chronic infection. The potentially oncogenic functions of HBx 
include the transcriptional activation of genes encoding proteins regulating cell growth, apoptosis 
modulation and the inhibition of nucleotide excision repair following DNA damage. HBx exerts its 
effects by interacting with cellular proteins and activating cell signaling pathways (3, 4). 
The pathogenesis of HBV infection involves the selection and expression of several common viral 
mutants. HBV genes have overlapping open reading frames. A mutation in the HBV genome may 
therefore have effects on several proteins. The HBx gene overlaps regions of crucial importance for 
viral replication, such as the direct repeat sequences DR1 and DR2, the preC/C gene promoter and the 
enhancer II region. The common double mutation in the HBV basic core promoter (BCP) region 
A1762T/G1764A corresponds to a double mutation in codons 130 and 131 of the HBV X gene. The 
change in HBx amino-acid sequence (K130M and V131I) resulting from these T-A point mutations is 
associated with severe liver damage and HCC (5-8). These substitutions may be associated with an 
additional mutation at position 127 in the HBx protein, which has been detected in patients with HCC 
or fulminant hepatitis (9, 10). Natural mutations in the HBx gene are thought to lead to progression to 
chronic disease due to the abolition of anti-proliferative and apoptotic effects, causing uncontrolled 
growth and multistep hepatocarcinogenesis (11). The selection and expression of natural HBx mutants 
may have major implications for T-cell recognition of this protein. 
As HBV is mainly not directly cytopathic, the immune response to viral antigens is thought to be 
responsible for both liver disease and viral clearance following HBV infection. Patients with acute 
viral infection who successfully clear the virus display a multispecific polyclonal cytotoxic T-
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lymphocyte (CTL) response specific for a number of epitopes within the core, polymerase and 
envelope proteins (12-15). HBV-specific T helper (Th) cells are also activated and multispecific Th1-
like responses are detected in patients successfully clearing HBV after acute infection (16). This HBV-
specific T-cell response is weak or undetectable in patients who develop chronic infection (17). Little 
is known about the CTL directed against HBx protein in HBV-infected individuals (18, 19) or about 
HBx-specific CD4+ T cells and their cytokine profile during the course of viral infection (20). 
We characterized peripheral HBx-specific T cells in 52 patients with chronic HBV infection at the 
inactive carrier state of the disease, by measuring interferon-gamma (IFN-) and interleukin-10 (IL-
10) secretion after the activation of peripheral blood mononuclear cells (PBMC) with 15-mer peptides 
spanning the HBx sequence. We identified an immunodominant, promiscuous T-cell epitope, HBx 
126-140, located in the carboxy-terminal part of the protein and recognized by IFN--secreting CD4+ 
T cells in most patients. HBV core promoter mutations, which frequently occur during chronic 
infection, modify the sequence of this HBx-derived immunodominant CD4+ T-cell epitope. These 
mutant viral sequences were recognized by T cells specific for the HBx wild-type epitope only 
weakly, if at all. 
 
MATERIALS AND METHODS 
 
Patient population 
Fifty-two subjects with chronic HBV infection, in the inactive carrier state of the disease (21) with less 
than 100,000 HBV copies/ml were enrolled (see Table online). All were hepatitis B surface antigen 
(HBsAg)-positive, hepatitis B e antigen (HBeAg)-negative, anti-HBe antibodies-positive, had normal 
transaminase levels and no or low underlying liver disease. This group of patients is heterogeneous as 
it contains i) patients with persistently low HBV DNA levels, even falling to undetectable levels (< 
200 cp/ml) either spontaneously or after effective antiviral treatment and ii) patients with fluctuating 
levels of HBV DNA being nevertheless < 100,000 cp/ml. This sub-group may include patients 
carrying HBV viruses with preC or BCP mutations (22). Patients had received no antiviral treatment 
for at least six months before inclusion. All patients were 18 to 60 years old, had no 
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immunosuppression or infections associated with human immunodeficiency virus, hepatitis C virus or 
hepatitis D virus, or liver diseases other than HBV infection, and consumed less than 40 g of 
alcohol/d. HLA-DR genotyping was carried out with the Olerup SSPTM Genovision kit (Saltsjöbaden, 
Sweeden). Two blood samples were collected from each patient at a mean of 8 + 4 month interval. 
This study was approved by the ethics committee of hospital, and all participants gave informed, 
written consent for participation, in line with French ethical guidelines. 
 
Synthetic peptides 
Synthetic peptides were purchased from NeoMPS (Strasbourg, France). The consensus sequence of 
the HBx protein, obtained by comparing published HBx-encoding sequences in Genbank — 
MAARLCCQLDPARDVLCLRPVGAESRGRPLSGPLGTLSSPSPSAVPTDHGAHLSLRGLPVCAF
SSAGPCALRFTSARRMETTVNAHQILPKVLHKRTLGLSAMSTTDLEAYFKDCLFKDWEELGE
EIRLKVFVLGGCRHKLVCAPAPCNFFTSA — was covered by 29 15-mer peptides with 10-residue 
overlaps. Individual or pooled peptides were used to stimulate PBMCs in vitro and for the Elispot 
assay. Three peptide pools were used: pool A (peptides x1 to x10), pool B (peptides x11 to x20) and 
pool C (peptides x21 to x29). Two additional peptides corresponding to variant sequences of the wild-
type x26 peptide (HBx 126-140, EIRLKVFVLGGCRHK) were used: V2 (EIRLMIFVLGGCRHK) 
and V3 (ETRLMIFVLGGCRHK). Peptides were prepared at 1 mg/ml in water or 20% DMSO if 
required and stored at -20 °C until use. 
 
HLA-DR peptide-binding assays COULD BE PROVIDED ON LINE 
HLA-DR molecules were purified from homologous EBV cell lines by affinity chromatography, as 
previously described (23, 24). Binding to various HLA-DR molecules was assessed by competitive 
ELISA, as previously described (23, 24). We used the individual peptides of pool C and a 20-mer 
HBc-derived peptide (core 50-69; PHHTALRQAILCWGELMTLA) as competitors (25). Maximal 
binding was determined by incubating the biotinylated peptide with the MHC class II molecule in the 
absence of competitor. Binding specificity for each HLA-DR molecule was ensured by the choice of 
the biotinylated peptides as described previously (23, 24). Concentration of the peptide that prevented 
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50% of binding of the biotinylated peptide was evaluated (IC50). The reference peptide is the 
unlabelled form of the biotinylated peptide and corresponds to high binder. Their IC50 are the 
following: 2 nM for DRB1*0101; 403 nM for DRB1*0301; 38 nM for DRB1*0401; 6 nM for 
DRB1*0701; 6 nM for DRB1*1101; 170 nM for DRB1*1301; 26 nM for DRB1*1501; 15 nM for 
DRB3*0101; 10 nM for DRB4*0101 and 6 nM for DRB5*0101. Data are expressed as relative 
activity: ratio of the IC50 of the peptide by the IC50 of the reference peptide. 
 
In vitro expansion of the PBMC 
PBMC were suspended at 3 x 106 cells per ml in complete medium (RPMI 1640 medium, Life 
Technologies, Gaithersburg, MD) supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, non-
essential amino acids, 100 U/ml penicillin, 100 Ug/ml streptomycin and 10% human AB serum (Institut 
Jacques Boy, Reims, France) plus 20 ng/ml IL-7 (Roche, Meylan, France) and 100 pg/ml IL-12 (R&D 
Systems Inc., MN, USA), in 24-well plates. Cells were stimulated by incubation with peptide pools A, 
B and C (1 µg/ml of each peptide) or with individual peptides (10 µg/ml). Half the medium was 
replaced every three to four days with complete medium supplemented with recombinant IL-2 (50 
IU/ml) (Roche, Meylan, France). After 10 to 14 days of culture, HBx-specific IFN-- and IL-10-
producing cells were quantified by Elispot assays and intracellular cytokine staining. 
 
Elispot assay COULD BE PROVIDED ON LINE 
Sterile nitrocellulose HA 96-well plates (Millipore, Bedford, MA) were coated with 15 µg/ml anti-
IFN- mAb (clone 1-DIK; Mabtech, Stockholm, Sweden) in 0.1 M bicarbonate buffer (pH 9.6) or with 
10 µg/ml anti-IL-10 mAb (clone B-N10, Diaclone, Besançon, France) in PBS (pH 7.0). The wells 
were blocked and washed (26), then filled, in triplicate, with in vitro-stimulated cells (1 to 2 x 
105/well) in complete medium and the appropriate peptides (1 µg/ml), with medium alone used as a 
negative control and phorbol myristate acetate (25 ng/ml)/ionomycin (2 mg/ml) or staphylococcal 
enterotoxin B (500 ng/ml) (Sigma, St. Louis, MO, USA), as positive control. After 20 h of incubation 
at 37°C, plates were washed and incubated with 1 µg/ml biotinylated anti-IFN- mAb (clone 7B6-1; 
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Mabtech) or with 20 µg/ml biotinylated anti-IL-10 mAb (clone B-T10; Diaclone) for 2 h at room 
temperature. Plates were then washed and antibody binding was detected as previously described (26). 
A Zeiss Elispot automatic counter was used to score the number of spots. 
The specificity and cut-off of Elispot assays were determined with PBMC from healthy individuals 
(n=9) and with PBMC from hemochromatosis patients (n=2). These PBMC were subjected to in vitro 
expansion with HBx-derived peptides and tested in Elispot assays in experimental conditions identical 
to those used for PBMC from chronic HBV carriers. The cut-off of Elispot assays were 62 IFN-- and 
40 IL-10-spot-forming cells (SFC) per million PBMC, calculated as mean + 2 sd SFC per million 
PBMC from HBV-negative subjects. The response was considered positive if the median number of 
SFC in triplicate wells was at least twice than in control wells without peptide and was superior to the 
cut-off values. 
 
Inhibition of Elispot assays 
Class II HLA-restriction was determined, after in vitro expansion, by incubating PBMC for 90 min at 
37°C with 10 µg/ml of anti-class II HLA antibodies: anti-HLA-DR (L243) from ATCC, anti-HLA-DQ 
(SPVL3) and anti-HLA-DP (B7/21) kindly provided by Dr. Y. van de Wal (Department of Immuno-
hematology and Blood Bank, Leiden, The Netherlands). Anti-class I HLA-A2 antibody (BB7-2) was 
used as a negative control. Pre-incubated PBMC were then tested in Elispot assays, as described 
above. 
 
Intracellular staining  COULD BE PROVIDED ON LINE 
Populations of PBMC expanded in vitro were incubated overnight either with 500 ng/ml 
staphylococcal enterotoxin B (Sigma) as a positive control, with medium alone as a negative control or 
with individual HBx-derived peptides (1 µg/ml) and Brefeldin A (2 µg/ml) (Sigma). After washing, 
cells were stained with appropriate combinations of monoclonal antibodies — anti-CD3-APC (clone 
HIT3a; BD Pharmingen), anti-CD4-PE (clone RPA-T4; BD Pharmingen), anti-CD4-APC (clone RPA-
T4; Serotec) and/or anti-CD8-PerCP (clone SK1; BD Biosciences) — for 30 minutes at 4°C and 
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washed again. Cells were fixed, permeabilized and stained with anti-human IFN--FITC antibody 
(clone 4S.B3; BD Biosciences) and with anti-human IL-10-PE antibody (clone JES3-9D7; Serotec) for 
30 minutes at 4°C and washed again. At least 50,000 lymphocyte-gated events were acquired on a 
FACSCalibur flow cytometer (BD Biosciences) and analyzed with Cellquest (BD Biosciences). 
Background staining was assessed with an isotype-matched control monoclonal antibody and 
subtracted from all values. 
 
RESULTS 
 
Presence of HBx-specific IFN--secreting T cells in chronic HBV carriers 
We analyzed the HBx-specific IFN--secreting T-cell response by Elispot assays and the use of three 
peptide pools (A, B, C) covering the entire HBx sequence to stimulate PBMC from 52 chronic inactive 
carriers of HBV. HBx-specific IFN--secreting T cells were found in 36 of the 52 patients studied 
(69%): 28 (78%) had T cells recognizing epitopes in the carboxy-terminal part of HBx (pool C), 17 
(42%) had T cells specific for the central region of the protein (pool B) and 9 (25%) had T cells 
specific for epitopes in the amino-terminal part of the protein (pool A) (Figure 1A). The diversity of 
HBx-specific IFN--secreting T-cell responses to pools A, B and C is shown in Figure 1B. No more 
than 10% of patients displayed specific responses to all three peptide pools. 
 
Mapping of the IFN--secreting T-cell response to individual pool C peptides 
As most HBx-specific IFN--secreting T cells recognized the carboxy-terminal part of the protein, we 
mapped the single epitopes targeted by T cells in this region. PBMC from the 28 patients with pool C-
specific T cells were stimulated with the entire peptide pool C and with individual pool C peptides, 
and then tested in Elispot assays (Figure 2). T-cell activation following PBMC culture with the entire 
peptide pool resulted from specific stimulation with a single peptide, as 24 of the 28 patients (86%) 
had T cells specific for the x26 epitope (compare left and middle panels of Figure 2). Moreover, x26-
specific T cells were the only T cells reactive against the domain of the protein covered by peptide 
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pool C in at least 13 of the 28 patients (46%), and an absence of T cells recognizing the x26 epitope 
was noted in only four of these patients (patients P62, P34, P53 and P38). We analyzed PBMC from 
11 uninfected individuals to check the specificity of these responses. None had T cells responding to 
pool C or x26 peptides in Elispot assays after in vitro expansion (data not shown). 
T cells specific for individual pool C peptides other than x26 were detected in 8 patients (Figure 2, 
right panel). In the absence of x26-specific T-cell reactivity, T cells recognized the x22 peptide 
(patients P62, P53 and P38). In 5 of the 24 patients with x26-specific T cells, weak reactivity to x21 to 
x25 and x27 was also observed (patients P31, P46, P59, P28 and P23, right panel, Figure 2). With the 
exception of patient P23, whose T cells were more strongly activated with x25 than with x26, specific 
T-cell reactivity was 5 to 10 times higher for x26 than for other pool C single peptides (compare 
middle and right panels). 
In conclusion, IFN--secreting T cells recognizing the carboxy-terminal domain of HBx targeted a 
single immunodominant epitope. As this epitope was recognized by T cells from a large number of 
patients expressing different HLA molecules, x26 peptide may be considered a promiscuous epitope. 
 
HBx-derived peptides activated IFN-- and IL-10-secreting T cells in chronic HBV carriers 
Even if HBx-specific IFN--secreting T cells were found in PBMC from most of the studied patients, 
we asked whether IL-10 secretion can be detected in PBMC from IFN--Elispot-negative patients. We 
quantified and compared IFN- and IL-10 secretion after the in vitro expansion of PBMC from 31 
chronic HBV carriers with and without pool C-specific IFN--secreting T-cell responses. In 13 of the 
31 patients (42%), neither IFN-- nor IL-10-producing specific T cells were detected. No IL-10 
secretion was observed in 11 patients (35%) with IFN--secreting T-cell responses of various 
magnitudes (Figure 3A). Finally, only 7 of the 31 patients (23%) with generally strong IFN--secreting 
T-cell responses had detectable numbers of specific IL-10-secreting T cells (Figure 3B). Except in 
patient P26, the frequency of IFN--secreting T cells was always higher than that of IL-10-secreting T 
cells (Figure 3B). The IFN--secreting T-cell response was around ten times higher than the IL-10-
producing T-cell response in Elispot (range: 4.8 - 27.4 fold, median; 11.5). 
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IL-10 secretion was observed in only two and one of the 24 studied patients after the activation of 
PBMC with peptide pools A and B, respectively. IFN- secretion by activated T cells was detected 
simultaneously in these three patients with IL-10-producing T cells. Peptide pool A activated 505 IFN-
- and 170 IL-10-secreting T cells per million PBMC from patient P7 and 104 IFN-- and 313 IL-10-
SFC per million PBMC from patient P27. Finally, 652 IFN-- and 79 IL-10-SFC pool B-specific T 
cells per million PBMC were detected for patient P41. 
Overall, IL-10 secretion after T-cell activation with HBx-derived peptides was weak or undetectable. 
Studies focusing on the carboxy-terminal region showed that peptide pool C or x26 activated IFN--
production more efficiently than IL-10 production. 
 
Phenotype of x26-specific T cells 
We investigated whether the x26 epitope activated CD4+ or CD8+ T cells, by intracellular IFN-
staining of PBMC stimulated in vitro with x26. The phenotype of CD3+ IFN--producing x26-specific 
T cells from a representative patient (P30) is shown in Figure 4A. The promiscuous, immunodominant 
x26 peptide specifically stimulated CD4+ but not CD8+ T cells. This result was confirmed in 10 
patients with x26-positive response. 
The x26-specific T-cell response of patient P26 was further characterized by intracellular staining of 
both IFN- and IL-10, to identify more precisely the T cells producing either or both cytokines. We 
found that 7.66% CD4+ T cells produced IFN- Zand 0.73 % produced IL-10 (Figure 4B, left and 
central panels)[ However, most CD4+ T cells activated by x26 (6.95% of total CD4+ T cells) produced 
IFN- but not IL-10 (Figure 4B, right panel). Less than 10% of the x26-specific CD4+ T-cell 
population (0.73% of total CD4+ T cells) produced IL-10 together with IFN-. No activated T cells 
producing IL-10 only were observed. 
This is consistent with the small number of IL-10-producing T cells identified by Elispot and 
highlights the more precise quantification of IFN- and IL-10 by intracellular staining than by Elispot 
assays when these cytokines are produced simultaneously (compare Figures 3B and 4B). 
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HLA class II restriction of x26 peptide 
We used three experimental approaches to characterize the HLA class II-restriction of x26. After in 
vitro expansion, PBMC were incubated with anti-HLA-DR, anti-HLA-DQ or anti-HLA-DP antibodies 
and tested in Elispot assays. Prior incubation with anti-HLA-DR antibodies inhibited IFN--secretion 
upon stimulation with x26 by at least 80%. No such effect was observed after the prior incubation of 
PBMC with anti-HLA-DP or anti-HLA-DQ antibodies, or with irrelevant control anti-HLA-A2 
antibodies (Figure 5). The x26 epitope is therefore presented by HLA-DR molecules. 
We assessed the capacity of x26 and of other pool C peptides to bind to various purified HLA-DR 
molecules. An HBcAg-derived peptide, c59-60, described as HBV promiscuous epitope (25) was 
tested in parallel (Table 1). High-affinity binding was observed for x25 peptide with at least 4 of the 
10 HLA-DR molecules tested (DRB1*0301, DRB1*1101, DRB1*1301 and DRB1*1501). The x26 
peptide could be presented by the HLA-DRB1*0101, HLA-DR01*0401, HLA-DRB1*1301 and HLA-
DRB5*0101 molecules. DRB1*1301 molecules could bind x22, x23 and x27 peptides as well, while 
x22 also bound to DRB4*0101. In comparison, the HBcAg-derived promiscuous epitope exhibited a 
good affinity for DRB1*0301, DRB1*1301 and DRB1*1501. 
Finally, we genotyped the HLA-DR molecules of 30 inactive HBV carriers with or without x26-
specific T cells. For the HLA-DRB1 gene, the prevalence of alleles DRB1*0301 (9/30), 
DRB1*0401(9/30), DRB1*1101 (9/30) and DRB1*1301 (7/30) was high among the studied patients. 
In 16 patients, the presence or absence of HLA-DR alleles binding x26 (HLA-DRB1*0101, HLA-
DR01*0401, HLA-DRB1*1301 and HLA-DRB5*0101) was found to be related to specific IFN--
secreting T-cell reactivity (Table 2).  
 
Recognition of viral mutants by x26-specific T cells 
Some HBx mutations in basic core promoter mutant viruses concern the x26 epitope. An analysis of 
sequences from 40 cloned HBV genomes published in GenBank (http://www.ncbi.nlm.nih.gov) shows 
that the frequent codon 130 and 131 (K130M and V131I) mutations were present in 12 of the 40 
sequences. Codon 127 (I127T) mutation occurred in 4 of the 40 HBx sequences.  We therefore 
evaluated the recognition of viral sequence variants by x26-specific T cells. For PBMC stimulation in 
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vitro, we used x26 peptide, covering the wild-type epitope, separately or mixed with the peptides V2 
and V3, corresponding to viral mutant sequences. No activation of x26-specific T cells by the variant 
peptides V2 and V3 was found in 10 of 13 patients with x26-specific T-cell responses (Figure 6). 
When the three peptides were used for in vitro expansion (Figure 6 right panel), markedly fewer cells 
were recalled in only three patients in Elispot assay with the variant peptides. None of 12 patients with 
x26-negative T-cell responses in IFN- Elispot assays had T-cell responses to variant peptides (not 
shown). 
We investigated whether mutant peptides activated IL-10- rather than IFN--secreting T cells, by 
assessing cytokine secretion after the stimulation of PBMC with V2 and V3. No IL-10-secreting T 
cells were found in 15 studied patients with (n=6) or without (n=9) x26-specific IFN--secreting T 
cells. In conclusion, viral mutant sequences activated T cells specific for the x26 epitope much less 
efficiently and no cross-recognition of variant sequences by x26 specific-T cells was found. 
 
Sequencing of HBV viral DNA from patients 
We next investigate if HBV genome from patients may have viral mutations affecting the x26 epitope. 
Sequencing of the x26 encoding HBV DNA region could be performed only on three samples (P48, 
P59, P46) with HBV viral load exceeding 2x104 copies /ml and detectable HBV DNA after nested 
PCR (see online figure).  For patients P48 and P59, A-T and G-A mutations at nucleotides 1762 and 
1764 were found in HBV genome, changing amino acid in the HBx protein at positions K130M and 
V131I. Clinical data from patient P48 shows that this patient was infected at birth with an HBeAg-
negative mutant (see online Table). X26 T-cell response was found negative in this patient (see Table 
2). In contrast, in patient P59 carrying a virus with BCP mutation, x26-specific T cells were detected 
in PBMC taken at the time of DNA sequencing (Figure 2). Finally, the amplified virus from patient 
P46 with x26-specific T-cell response (Figure 2) showed a wild type BCP sequence.  
This indicates that HBV variants with BCP mutations can be found in some of our patients at the 
inactive carrier state of the disease.  
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DISCUSSION 
 
HBV-specific CD4+ T cells play an important role in HBV infection, secreting the Th1 cytokines that 
downregulate HBV replication (27) and by contributing to the induction and maintenance of efficient 
CD8+ T-cell and B-cell responses (28). CD4+ T-cell epitopes have been identified in the core protein 
(25), HBe antigen (29), envelope (30) and polymerase proteins (31). Immune responses to HBx 
protein are poorly documented, with only one study dealing with CD4+ T-cell responses (20). In an 
attempt to define more accurately the breadth and epitope specificity of T-cell responses to HBx 
protein, we carried out a systematic analysis of T cells from 52 chronic HBV carriers. Following in 
vitro stimulation with pools of peptides covering the HBx sequence, IFN--secreting T cells specific 
for HBx were detected in 69% of patients, and in 67% (24/36) of them CD4+ T cells could be defined. 
This contrasts with the low prevalence of the Th cell responses against structural HBV proteins 
usually detected during chronic HBV infection. In this study, using the core 50-69 peptide (25, 32) for 
stimulation of PBMC and our cutured Elispot assay, IFN--secreting T-cell response was found in 3 
out of 8 patients, but with a ten fold lower number of specific T cells (data not shown). Previous 
studies have found that HLA-class II-restricted nucleocapsid antigen-specific Th cell responses are 
only detectable transiently during hepatitis exacerbation (14, 33). The CD4+ T-cell response to 
envelope proteins is markedly reduced during chronic HBV infection (1, 34). The high prevalence of 
IFN--secreting HBx-specific T cells reported here may be due to the protein itself or to the clinical 
status of the patients, i.e. HBV carriers in the inactive stage of the disease with less than 100,000 HBV 
copies/ml. The presence of HBx-specific CD4+ T cells during chronic infection may reflect T-cell 
activation due to the release of HBx protein by apoptotic hepatocytes during viral replication. The 
persistence of HBx-specific T cells could be related to the small amounts of HBx produced by infected 
hepatocytes, preventing the deletion or anergy of specific T cells occurring with other highly 
expressed viral antigens, such as HBsAg or HBcAg.  The impact of viral load on antiviral T-cell 
responses has been characterized in mouse models of chronic infection and in humans (35). T-cell 
responses to HBV antigens are detected more easily in patients with less than 107 copies/ml or after 
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successful antiviral treatment (36, 37). Consistent with these data, we found x26-specific T cells after 
stimulation of PBMC from only 1 of 13 patients with chronic active hepatitis and >105 copies/ml (data 
not shown).  
In contrast to the high prevalence of IFN--secreting HBx-specific T cells, IL-10-secreting T cells 
were detected in very few of the studied patients, always in the presence of IFN- production. This is 
consistent with previous reports of IL-12-induced IFN-/IL-10-secreting T cells generated in response 
to chronic infection (38, 39). Regulatory T cells specific for HBx, producing IL-10, are therefore 
unlikely to exist in our group of patients (40). This contrasts with HCV persistent infection, which is 
associated with enhanced IL-10 production in response to non-structural HCV antigens such as NS3, 
IL-10-producing T cells in the liver and weak CD4+ Th 1 reactivity in the periphery (16, 41). 
We observed a high prevalence of peripheral CD4+ T-cell responses principally targeting the C-
terminal part of HBx. This finding is in agreement with a previous report characterizing T-cell clones 
recognizing peptides within this domain of HBx (20). Remarkably, most of our patients had IFN--
secreting CD4+ T cells recognizing a previously unidentified single peptide, HBx 126-140 referred 
here to x26. In addition, x26 peptide was immunogenic in the context of multiple HLA-class II 
molecules and may therefore be considered a promiscuous epitope. Nevertheless, some patients with 
x26-specific T cells lack the HLA-DR molecules that bound the peptide with high affinity in vitro.
Other class II molecules not tested here are therefore probably able to bind x26. The partial correlation 
between the HLA-DR-restriction of the peptides and the pattern of DR alleles from different donors is 
consistent with published findings (31, 42). 
Chronic HBV infection evolves from an initial HBeAg-positive phase, through HBe seroconversion to 
an HBeAg-negative phase in which replication levels are lower. This process is characterized by a 
progressive switch from viral quasi-species dominated by “wild-type” variants lacking precore or core 
promoter mutations, to viral quasi-species in which precore or core promoter variants predominate 
(43, 44). But it was recently shown that precore and core promoter mutations exist in a substantial 
proportion of patients before HBeAg clearance (22). What role do x26-specific IFN--secreting T cells 
play against both wild-type and mutated x26-derived sequences? The effector properties of x26-
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specific T cells may constitute an immune system pressure against which these mutant viral variants 
are selected. 
The lack of recognition of variant HBx peptides, corresponding to BCP mutant sequences, by x26-
specfic T cells could not be explained by a decreased binding capacity of these sequences to HLA-DR 
molecules, as shown by comparative binding studies with the x26, V2 and V3 peptides and purified 
class II molecules (data not shown). Although core promoter mutations may appear early in HBV 
infection (8), the possibility of initial infection with the mutant virus cannot be excluded. This is the 
case for patient P48 who was infected at birth with an HBeAg-negative virus, and lacked for x26-
specific T-cell response. On the other hand, a wild-type sequence virus was found in patient P46 
concomitantly with detectable x26-specific T cells. However, for other patients such as P59 who were 
initially infected with a “wild-type” variant lacking core promoter mutations, x26-specific memory T 
cells may exist and can be detected in our assay despite the presence of a core promoter variant viral 
quasi-species at the time of blood collection. Our study shows that HBV strains with mutations 
affecting the immunodominant HBx epitope are likely to induce weaker T-cell responses, favoring the 
accumulation of such mutant strains. 
Mutations resulting in HBx protein truncation have also been associated with low levels of HBV 
replication and decreases in hepatitis activity in anti-HBe antibody-positive HBV carriers (45). Thus, 
at least some of the studied chronic carriers may produce truncated HBx. The presence of BCP 
mutants or truncated HBx mutants might account for the lack of T-cell reactivity specific for the wild-
type x26 peptide in some of our patients. Therefore, x26 and variant peptides could be used for the 
immunomonitoring of HBV sequence changes during disease progression. This hypothesis should be 
tested in longitudinal studies in groups of patients differing in clinical status. 
In addition, the immunogenicity, the promiscuous HLA-DR binding and the efficient activation of 
specific IFN--secreting T cells of this newly described HBx epitope suggest that it is a potential 
candidate for use in therapeutic vaccines for patients with chronic HBV infection. 
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Legends to Figures 
Figure 1. Presence and diversity of HBx-specific IFN--secreting T cells in 52 patients with chronic HBV 
infection. PBMCs were stimulated in vitro with HBx-derived 15-mer peptides covering the whole HBx 
sequence, divided into pools A, B and C. IFN--secreting T cells were determined by Elispot, using the same 
peptide pools. The proportion of patients testing positive is indicated on the top of each column. A) Percentage 
of patients with undetectable HBx-specific T cells (white column) and with HBx-specific T cells activated with 
each peptide pool (gray columns); B) diversity of recognition of regions within the HBx protein by HBx-specific 
T cells (gray striped columns). 
 
Figure 2. IFN--secreting T cells upon stimulation with peptide pool C and mapping of the T-cell response to 
single peptides. Number of IFN--secreting T cells determined by Elispot and expressed as the number of 
specific spot-forming cells (SFC)/106 PBMCs after in vitro stimulation with peptide pool C (left panel), 
individual peptide x26 (middle panel), and single peptides or groups of peptides from pool C with the exception 
of x26 peptide (right panel). In the right panel, the number of SFC is indicated on each bar. The scale of the right 
panel differs from that of the left and central panels. ND: not done. 
 
Figure 3. IFN-- and IL-10-secreting T cells determined by Elispot assays after in vitro stimulation of PBMC 
with the entire peptide pool C or x26 alone. Number of IFN-- or IL-10 spot-forming cells (SFC)/106 PBMC 
(black and gray columns, respectively) of 11 patients with only IFN--secreting T cells (A panel) and 7 patients 
with both IFN-- and IL-10-secreting T cells (B panel). Number of SFC is indicated on the top of each column. 
The cutoff points for Elispot assays are 62 IFN-- and 40 IL-10-SFC/106 PBMC. 
 
Figure 4. Phenotype of x26-specific T cells after in vitro expansion from PBMC with x26. A) Percentages of 
IFN--secreting CD3+ CD4+ (left panel) or CD3+ CD8+ (right panel) specific T cells are shown, B) within the 
CD4+ T-cell population, the percentages of x26-specific CD4+ T cells secreting IFN- (left panel), IL-10 
(central panel) and IL-10 and/or IFN- (right panel) are shown. 
 
Figure 5. Anti-MHC class II antibody-mediated inhibition of IFN- secretion by x26-specific T cells. PBMC 
expanded in vitro with peptide x26 were first incubated with anti-class II HLA antibodies — anti-HLA-DR, anti-
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HLA-DQ or anti-HLA-DP — or with an irrelevant antibody (anti-HLA-A2). PBMC were then tested in Elispot 
assays as described in Materials and Methods. Results obtained with three representative patients are shown. 
 
Figure 6. Recognition of viral mutants by x26-specific T cells. PBMC from 13 patients with known x26-
specific IFN--producing T cells were expanded in vitro separately with x26 peptide (left panel) or with a 
mixture of x26, V2 and V3 peptides (right panel). IFN--secretion after the activation with each of the three 
peptides in Elispot assays is shown. 
 
Figure online. Amino acid sequence of x26 region. 
 
Legends to Tables 
Table (available online). Clinical, virological and immunological characteristics of patients included in this 
study. 
 
Table 1. Binding of HBx-derived peptides to immunopurified class II HLA molecules. Data are expressed as 
relative activity: ratio of the IC50 of the peptide to the IC50 of the reference peptide. The relative activities of pool 
C peptides and an HBcAg-derived peptide (c50-69) are shown. Boldface indicates relative binding affinity below 
100 and corresponds to good binders. 
 
Table 2. Comparative analysis of patients’ HLA-DR genotypes, x26-binding HLA-DR molecules and x26-
specific IFN--secreting T-cell responses. Brackets for DRB1 genotype indicate that heterozygosity could not be 
confirmed with the current assay. (#) HLA-DR molecules binding x26, as shown in Table 1 for DRB1*0101, 
DRB1*0401, DRB1*1301 and DRB5*0101. (##) determined by Elispot assays and expressed as ranges of IFN-
-SFC per million PBMC: + 100-500; ++ 500-1000; +++ 1000-2000 and ++++ >2000. 
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Figure 2. Malmassari et al.
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Figure 6. Malmassari et al. 
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Figure available online
Amino acid sequence of x26 region. Sequencing of HBV viral DNA was performed for three patients: P48, P59 
and P46. Part of the preC gene was amplified using two couples of primers in a nested PCR (1680-1962 outer 
primers and 1705-1940 inner primers). PCRs were performed using a Thermal Cycler 9700 Gold (Perkin Elmer, 
CA) under the following conditions: 5 cycles, each comprising 15 s at 94 °C, 30 s at 50 °C and 45 s at 72 °C; 
then 35 cycles, each comprising 15 s at 94 °C, 30 s at 55 °C and 45 s at 72 °C. PCR results were analysed by 
electrophoresis on a 2% agarose gel stained with ethidium bromide. *HBx consensus sequence obtained by 
comparing published HBx-encoding sequences in Genbank (see Materials and Methods); **two different 
samples from P48 taken at one year interval. Amino acid positions of mutant sequences on HBx protein are 
indicated.
13
0
13
1
Consensus*  GLSAMSTTDLEAYFKDCLFKDWEELGEEIRLKVFVLGGCRHKLVCAPAPCNFFTSA
P48**       -------..........V.............MI.......................
P48         ....R............V.............MI.......................
P59         ..P..............V.............MI.......................
P46         ------------.....V......................................
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HLA class II molecules Peptides
DRB1 
*0101 
DRB1 
*0301 
DRB1 
*0401 
DRB1 
*0701 
DRB1 
*1101 
DRB1 
*1301 
DRB1 
*1501 
DRB3 
*0101 
DRB4 
*0101 
DRB5 
*0101 
x21 >5,848 >25 >261 >1,547 >1,754 >59 >377 155 135 >1,805
x22 4,455 >25 247 >1,547 >1,754 41 245 783 77 >1,805
x23 4,160 >25 >261 >1,547 >1,754 41 >377 >656 >1,032 >1,805
x24 2,412 >25 >261 >1,547 >1,754 >59 >377 >656 >1,032 1,122 
x25 814 1 158 135 4 6 40 347 519 >1,805
x26 1 >25 17 >1,547 900 55 112 >656 224 31 
x27 1,662 >25 >261 1,111 1,400 10 >377 >656 >1,032 >1,805
x28 766 >25 133 >1,547 >1,754 >59 195 >656 154 313 
x29 2,932 >25 200 540 >1,754 >59 144 >656 549 1,700 
c50-69 215 7 131 360 408 15 20 >656 285 171 
 
Table 1. 
Binding of HBx-derived peptides to immunopurified class II HLA molecules. Data are expressed as relative 
activity: ratio of the IC50 of the peptide to the IC50 of the reference peptide. The relative activities of pool C 
peptides and an HBc-derived peptide (c50-69) are shown. Boldface indicates relative binding affinity below 100 
and corresponds to good binders. 
Page 33 of 64
Hepatology
Hepatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
H
al-Pasteur author m
anuscript    pasteur-00141277, version 1
For Peer Review
HLA-DR genotype Presence of HLA-DR with x26-specific IFN--secretingPatients 
DRB1 DRB3 DRB4 DRB5 x26-binding capacity # T cells ## 
P32 *0701, *0901  - No negative 
P8 *0301 - No negative 
P64 *0801, *0901  - No negative 
P44 *0301 - No negative 
P34 *0301, *0701 - - No negative 
P3 *0301, *1301 - Yes ++ 
P41 *0101, *0401   - Yes ++ 
P45 *1101, *1301 - Yes ++++ 
P11 *0301, *1301 - Yes + 
P30 *0401, *1101 - - Yes +++ 
P27 *0401, *1301 - - Yes + 
P50 *0101, *0301 - Yes + 
P59 *0401, *1101 - - Yes ++++ 
P46 *1101, *1301 - Yes ++++ 
P12 *0301, *1301 - Yes + 
P31 *0101, *1501   - Yes +++ 
P23 *0301 (*1367) - No + 
P35 *0301, *1101 - No ++ 
P6 *0701, *1101 - - No +++ 
P51 *1101, *1201 - No +++ 
P26 *1101, *1201 - No +++ 
P47 *1101, *1201 - No +++ 
P13 *0401, *1301 - - Yes negative 
P1 *0401, *0701  - Yes negative 
P2 *0801, *1501   - Yes negative 
P48 *0401, *1401 - - Yes negative 
P4 *0401 (*1367)  - Yes negative 
P38 *1201, *1501 - - Yes negative 
P53 *0101, *0401  - Yes negative 
P62 *0101, *1501   - Yes negative  
 
Table 2. Comparative analysis of patients’ HLA-DR genotypes, x26-binding HLA-DR molecules and x26-specific 
IFN--secreting T-cell responses. Brackets for DRB1 genotype indicate that heterozygosity could not be confirmed with 
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the current assay. (#) HLA-DR molecules binding x26, as shown in Table 1 for DRB1*0101, DRB1*0401, DRB1*1301 
and DRB5*0101. (##) determined by Elispot assays and expressed as ranges of IFN--SFC per million PBMC: + 100-
500; ++ 500-1000; +++ 1000-2000 and ++++ >2000. 
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ABSTRACT
The hepatitis B X (HBx) protein is a crucial component in hepatitis B virus (HBV) infection in vivo
and has been implicated in hepatocellular carcinoma. In this study, we aimed to detect and characterize 
peripheral HBx-specific T cells in chronically infected patients at the inactive carrier state of the 
disease. HBx-specific IFN--secreting T cells were found in 36 of 52 patients (69%) and 78% (28/36) 
of responding patients had T cells targeting epitopes in the carboxy-terminal part of HBx. IL-10 
secretion following the stimulation of T cells with HBx-derived peptides was weak or undetectable. 
IFN--secreting T cells recognized a previously unknown immunodominant CD4+ T-cell epitope, 
HBx 126-140 (EIRLKVFVLGGCRHK), in 86% (24/28) of patients. This peptide bound several HLA-
DR molecules (HLA-DRB1*0101, HLA-DRB1*0401, HLA-DRB1*1301 and HLA-DRB5*0101). Its 
coding sequence overlaps a domain of the HBV genome encompassing the basic core promoter (BCP) 
region. Taking into account the selection of viral core promoter mutants during HBV infection, we 
found that HBV variants with BCP mutations were present in patient sera. We further demonstrated 
that these viral mutant sequences activated T cells specific for the immunodominant epitope only 
weakly, if at all. This is the first study linking BCP mutations and HBx-specific T-cell responses.
Therefore, wild type and variant peptides may represent potentially tools for monitoring the HBV-
specific T-cell responses involved in sequence evolution during disease progression. Finally, the 
degenerate HLA-DR binding of this promiscuous, immunodominant peptide would make it a valuable 
component of vaccines for protecting large and ethnically diverse patient populations. 
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INTRODUCTION 
An effective vaccine against hepatitis B virus (HBV) infection has been available for more than two 
decades, but 400 million people —more than 5% of the world's population — are chronically infected 
with HBV, and  more than 1 million people die each year from HBV-related liver cirrhosis and 
hepatocellular carcinoma (HCC) (1, 2).
The hepatitis B X (HBx) protein is a key element in HBV infection in vivo and has been implicated in 
HCC development. HBx is well conserved among mammalian hepadnaviruses and is produced very 
early after infection and throughout chronic infection. The potentially oncogenic functions of HBx 
include the transcriptional activation of genes encoding proteins regulating cell growth, apoptosis 
modulation and the inhibition of nucleotide excision repair following DNA damage. HBx exerts its 
effects by interacting with cellular proteins and activating cell signaling pathways (3, 4).
The pathogenesis of HBV infection involves the selection and expression of several common viral 
mutants. HBV genes have overlapping open reading frames. A mutation in the HBV genome may 
therefore have effects on several proteins. The HBx gene overlaps regions of crucial importance for 
viral replication, such as the direct repeat sequences DR1 and DR2, the preC/C gene promoter and the 
enhancer II region. The common double mutation in the HBV basic core promoter (BCP) region 
A1762T/G1764A corresponds to a double mutation in codons 130 and 131 of the HBV X gene. The 
change in HBx amino-acid sequence (K130M and V131I) resulting from these T-A point mutations is 
associated with severe liver damage and HCC (5-8). These substitutions may be associated with an 
additional mutation at position 127 in the HBx protein, which has been detected in patients with HCC 
or fulminant hepatitis (9, 10). Natural mutations in the HBx gene are thought to lead to progression to 
chronic disease due to the abolition of anti-proliferative and apoptotic effects, causing uncontrolled 
growth and multistep hepatocarcinogenesis (11). The selection and expression of natural HBx mutants 
may have major implications for T-cell recognition of this protein.
As HBV is mainly not directly cytopathic, the immune response to viral antigens is thought to be 
responsible for both liver disease and viral clearance following HBV infection. Patients with acute 
viral infection who successfully clear the virus display a multispecific polyclonal cytotoxic T-
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lymphocyte (CTL) response specific for a number of epitopes within the core, polymerase and 
envelope proteins (12-15). HBV-specific T helper (Th) cells are also activated and multispecific Th1-
like responses are detected in patients successfully clearing HBV after acute infection (16). This HBV-
specific T-cell response is weak or undetectable in patients who develop chronic infection (17). Little 
is known about the CTL directed against HBx protein in HBV-infected individuals (18, 19) or about 
HBx-specific CD4+ T cells and their cytokine profile during the course of viral infection (20).
We characterized peripheral HBx-specific T cells in 52 patients with chronic HBV infection at the 
inactive carrier state of the disease, by measuring interferon-gamma (IFN-) and interleukin-10 (IL-
10) secretion after the activation of peripheral blood mononuclear cells (PBMC) with 15-mer peptides 
spanning the HBx sequence. We identified an immunodominant, promiscuous T-cell epitope, HBx 
126-140, located in the carboxy-terminal part of the protein and recognized by IFN--secreting CD4+ 
T cells in most patients. HBV core promoter mutations, which frequently occur during chronic 
infection, modify the sequence of this HBx-derived immunodominant CD4+ T-cell epitope. These 
mutant viral sequences were recognized by T cells specific for the HBx wild-type epitope only 
weakly, if at all.
MATERIALS AND METHODS
Patient population
Fifty-two subjects with chronic HBV infection, in the inactive carrier state of the disease (21) with less 
than 100,000 HBV copies/ml were enrolled (see Table online). All were hepatitis B surface antigen 
(HBsAg)-positive, hepatitis B e antigen (HBeAg)-negative, anti-HBe antibodies-positive, had normal 
transaminase levels and no or low underlying liver disease. This group of patients is heterogeneous as 
it contains i) patients with persistently low HBV DNA levels, even falling to undetectable levels (< 
200 cp/ml) either spontaneously or after effective antiviral treatment and ii) patients with fluctuating 
levels of HBV DNA being nevertheless < 100,000 cp/ml. This sub-group may include patients 
carrying HBV viruses with preC or BCP mutations (22). Patients had received no antiviral treatment 
for at least six months before inclusion. All patients were 18 to 60 years old, had no 
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immunosuppression or infections associated with human immunodeficiency virus, hepatitis C virus or 
hepatitis D virus, or liver diseases other than HBV infection, and consumed less than 40 g of 
alcohol/d. HLA-DR genotyping was carried out with the Olerup SSPTM Genovision kit (Saltsjöbaden, 
Sweeden). Two blood samples were collected from each patient at a mean of 8 + 4 month interval. 
This study was approved by the ethics committee of hospital, and all participants gave informed, 
written consent for participation, in line with French ethical guidelines.
Synthetic peptides
Synthetic peptides were purchased from NeoMPS (Strasbourg, France). The consensus sequence of 
the HBx protein, obtained by comparing published HBx-encoding sequences in Genbank —
MAARLCCQLDPARDVLCLRPVGAESRGRPLSGPLGTLSSPSPSAVPTDHGAHLSLRGLPVCAF
SSAGPCALRFTSARRMETTVNAHQILPKVLHKRTLGLSAMSTTDLEAYFKDCLFKDWEELGE
EIRLKVFVLGGCRHKLVCAPAPCNFFTSA — was covered by 29 15-mer peptides with 10-residue 
overlaps. Individual or pooled peptides were used to stimulate PBMCs in vitro and for the Elispot 
assay. Three peptide pools were used: pool A (peptides x1 to x10), pool B (peptides x11 to x20) and 
pool C (peptides x21 to x29). Two additional peptides corresponding to variant sequences of the wild-
type x26 peptide (HBx 126-140, EIRLKVFVLGGCRHK) were used: V2 (EIRLMIFVLGGCRHK) 
and V3 (ETRLMIFVLGGCRHK). Peptides were prepared at 1 mg/ml in water or 20% DMSO if 
required and stored at -20 °C until use.
HLA-DR peptide-binding assays COULD BE PROVIDED ON LINE
HLA-DR molecules were purified from homologous EBV cell lines by affinity chromatography, as 
previously described (23, 24). Binding to various HLA-DR molecules was assessed by competitive 
ELISA, as previously described (23, 24). We used the individual peptides of pool C and a 20-mer 
HBc-derived peptide (core 50-69; PHHTALRQAILCWGELMTLA) as competitors (25). Maximal 
binding was determined by incubating the biotinylated peptide with the MHC class II molecule in the 
absence of competitor. Binding specificity for each HLA-DR molecule was ensured by the choice of 
the biotinylated peptides as described previously (23, 24). Concentration of the peptide that prevented 
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50% of binding of the biotinylated peptide was evaluated (IC50). The reference peptide is the 
unlabelled form of the biotinylated peptide and corresponds to high binder. Their IC50 are the 
following: 2 nM for DRB1*0101; 403 nM for DRB1*0301; 38 nM for DRB1*0401; 6 nM for 
DRB1*0701; 6 nM for DRB1*1101; 170 nM for DRB1*1301; 26 nM for DRB1*1501; 15 nM for 
DRB3*0101; 10 nM for DRB4*0101 and 6 nM for DRB5*0101. Data are expressed as relative 
activity: ratio of the IC50 of the peptide by the IC50 of the reference peptide.
In vitro expansion of the PBMC
PBMC were suspended at 3 x 106 cells per ml in complete medium (RPMI 1640 medium, Life 
Technologies, Gaithersburg, MD) supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, non-
essential amino acids, 100 U/ml penicillin, 100 µg/ml streptomycin and 10% human AB serum (Institut 
Jacques Boy, Reims, France) plus 20 ng/ml IL-7 (Roche, Meylan, France) and 100 pg/ml IL-12 (R&D 
Systems Inc., MN, USA), in 24-well plates. Cells were stimulated by incubation with peptide pools A, 
B and C (1 µg/ml of each peptide) or with individual peptides (10 µg/ml). Half the medium was 
replaced every three to four days with complete medium supplemented with recombinant IL-2 (50 
IU/ml) (Roche, Meylan, France). After 10 to 14 days of culture, HBx-specific IFN-- and IL-10-
producing cells were quantified by Elispot assays and intracellular cytokine staining.
Elispot assay COULD BE PROVIDED ON LINE
Sterile nitrocellulose HA 96-well plates (Millipore, Bedford, MA) were coated with 15 µg/ml anti-
IFN- mAb (clone 1-DIK; Mabtech, Stockholm, Sweden) in 0.1 M bicarbonate buffer (pH 9.6) or with 
10 µg/ml anti-IL-10 mAb (clone B-N10, Diaclone, Besançon, France) in PBS (pH 7.0). The wells 
were blocked and washed (26), then filled, in triplicate, with in vitro-stimulated cells (1 to 2 x 
105/well) in complete medium and the appropriate peptides (1 µg/ml), with medium alone used as a 
negative control and phorbol myristate acetate (25 ng/ml)/ionomycin (2 mg/ml) or staphylococcal 
enterotoxin B (500 ng/ml) (Sigma, St. Louis, MO, USA), as positive control. After 20 h of incubation 
at 37°C, plates were washed and incubated with 1 µg/ml biotinylated anti-IFN- mAb (clone 7B6-1; 
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Mabtech) or with 20 µg/ml biotinylated anti-IL-10 mAb (clone B-T10; Diaclone) for 2 h at room 
temperature. Plates were then washed and antibody binding was detected as previously described (26). 
A Zeiss Elispot automatic counter was used to score the number of spots.
The specificity and cut-off of Elispot assays were determined with PBMC from healthy individuals 
(n=9) and with PBMC from hemochromatosis patients (n=2). These PBMC were subjected to in vitro
expansion with HBx-derived peptides and tested in Elispot assays in experimental conditions identical 
to those used for PBMC from chronic HBV carriers. The cut-off of Elispot assays were 62 IFN-- and 
40 IL-10-spot-forming cells (SFC) per million PBMC, calculated as mean + 2 sd SFC per million 
PBMC from HBV-negative subjects. The response was considered positive if the median number of 
SFC in triplicate wells was at least twice than in control wells without peptide and was superior to the 
cut-off values.
Inhibition of Elispot assays
Class II HLA-restriction was determined, after in vitro expansion, by incubating PBMC for 90 min at 
37°C with 10 µg/ml of anti-class II HLA antibodies: anti-HLA-DR (L243) from ATCC, anti-HLA-DQ 
(SPVL3) and anti-HLA-DP (B7/21) kindly provided by Dr. Y. van de Wal (Department of Immuno-
hematology and Blood Bank, Leiden, The Netherlands). Anti-class I HLA-A2 antibody (BB7-2) was 
used as a negative control. Pre-incubated PBMC were then tested in Elispot assays, as described 
above.
Intracellular staining  COULD BE PROVIDED ON LINE
Populations of PBMC expanded in vitro were incubated overnight either with 500 ng/ml 
staphylococcal enterotoxin B (Sigma) as a positive control, with medium alone as a negative control or 
with individual HBx-derived peptides (1 µg/ml) and Brefeldin A (2 µg/ml) (Sigma). After washing, 
cells were stained with appropriate combinations of monoclonal antibodies — anti-CD3-APC (clone 
HIT3a; BD Pharmingen), anti-CD4-PE (clone RPA-T4; BD Pharmingen), anti-CD4-APC (clone RPA-
T4; Serotec) and/or anti-CD8-PerCP (clone SK1; BD Biosciences) — for 30 minutes at 4°C and 
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washed again. Cells were fixed, permeabilized and stained with anti-human IFN--FITC antibody 
(clone 4S.B3; BD Biosciences) and with anti-human IL-10-PE antibody (clone JES3-9D7; Serotec) for 
30 minutes at 4°C and washed again. At least 50,000 lymphocyte-gated events were acquired on a 
FACSCalibur flow cytometer (BD Biosciences) and analyzed with Cellquest (BD Biosciences). 
Background staining was assessed with an isotype-matched control monoclonal antibody and 
subtracted from all values.
RESULTS
Presence of HBx-specific IFN--secreting T cells in chronic HBV carriers
We analyzed the HBx-specific IFN--secreting T-cell response by Elispot assays and the use of three 
peptide pools (A, B, C) covering the entire HBx sequence to stimulate PBMC from 52 chronic inactive 
carriers of HBV. HBx-specific IFN--secreting T cells were found in 36 of the 52 patients studied 
(69%): 28 (78%) had T cells recognizing epitopes in the carboxy-terminal part of HBx (pool C), 17 
(42%) had T cells specific for the central region of the protein (pool B) and 9 (25%) had T cells 
specific for epitopes in the amino-terminal part of the protein (pool A) (Figure 1A). The diversity of 
HBx-specific IFN--secreting T-cell responses to pools A, B and C is shown in Figure 1B. No more 
than 10% of patients displayed specific responses to all three peptide pools.
Mapping of the IFN--secreting T-cell response to individual pool C peptides
As most HBx-specific IFN--secreting T cells recognized the carboxy-terminal part of the protein, we 
mapped the single epitopes targeted by T cells in this region. PBMC from the 28 patients with pool C-
specific T cells were stimulated with the entire peptide pool C and with individual pool C peptides, 
and then tested in Elispot assays (Figure 2). T-cell activation following PBMC culture with the entire 
peptide pool resulted from specific stimulation with a single peptide, as 24 of the 28 patients (86%) 
had T cells specific for the x26 epitope (compare left and middle panels of Figure 2). Moreover, x26-
specific T cells were the only T cells reactive against the domain of the protein covered by peptide 
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pool C in at least 13 of the 28 patients (46%), and an absence of T cells recognizing the x26 epitope 
was noted in only four of these patients (patients P62, P34, P53 and P38). We analyzed PBMC from 
11 uninfected individuals to check the specificity of these responses. None had T cells responding to 
pool C or x26 peptides in Elispot assays after in vitro expansion (data not shown).
T cells specific for individual pool C peptides other than x26 were detected in 8 patients (Figure 2, 
right panel). In the absence of x26-specific T-cell reactivity, T cells recognized the x22 peptide 
(patients P62, P53 and P38). In 5 of the 24 patients with x26-specific T cells, weak reactivity to x21 to 
x25 and x27 was also observed (patients P31, P46, P59, P28 and P23, right panel, Figure 2). With the 
exception of patient P23, whose T cells were more strongly activated with x25 than with x26, specific 
T-cell reactivity was 5 to 10 times higher for x26 than for other pool C single peptides (compare 
middle and right panels).
In conclusion, IFN--secreting T cells recognizing the carboxy-terminal domain of HBx targeted a 
single immunodominant epitope. As this epitope was recognized by T cells from a large number of 
patients expressing different HLA molecules, x26 peptide may be considered a promiscuous epitope.
HBx-derived peptides activated IFN-- and IL-10-secreting T cells in chronic HBV carriers
Even if HBx-specific IFN--secreting T cells were found in PBMC from most of the studied patients, 
we asked whether IL-10 secretion can be detected in PBMC from IFN--Elispot-negative patients. We 
quantified and compared IFN- and IL-10 secretion after the in vitro expansion of PBMC from 31 
chronic HBV carriers with and without pool C-specific IFN--secreting T-cell responses. In 13 of the 
31 patients (42%), neither IFN-- nor IL-10-producing specific T cells were detected. No IL-10 
secretion was observed in 11 patients (35%) with IFN--secreting T-cell responses of various 
magnitudes (Figure 3A). Finally, only 7 of the 31 patients (23%) with generally strong IFN--secreting 
T-cell responses had detectable numbers of specific IL-10-secreting T cells (Figure 3B). Except in 
patient P26, the frequency of IFN--secreting T cells was always higher than that of IL-10-secreting T 
cells (Figure 3B). The IFN--secreting T-cell response was around ten times higher than the IL-10-
producing T-cell response in Elispot (range: 4.8 - 27.4 fold, median; 11.5).
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IL-10 secretion was observed in only two and one of the 24 studied patients after the activation of 
PBMC with peptide pools A and B, respectively. IFN- secretion by activated T cells was detected 
simultaneously in these three patients with IL-10-producing T cells. Peptide pool A activated 505 IFN-
- and 170 IL-10-secreting T cells per million PBMC from patient P7 and 104 IFN-- and 313 IL-10-
SFC per million PBMC from patient P27. Finally, 652 IFN-- and 79 IL-10-SFC pool B-specific T 
cells per million PBMC were detected for patient P41.
Overall, IL-10 secretion after T-cell activation with HBx-derived peptides was weak or undetectable. 
Studies focusing on the carboxy-terminal region showed that peptide pool C or x26 activated IFN--
production more efficiently than IL-10 production.
Phenotype of x26-specific T cells
We investigated whether the x26 epitope activated CD4+ or CD8+ T cells, by intracellular IFN-
staining of PBMC stimulated in vitro with x26. The phenotype of CD3+ IFN--producing x26-specific 
T cells from a representative patient (P30) is shown in Figure 4A. The promiscuous, immunodominant 
x26 peptide specifically stimulated CD4+ but not CD8+ T cells. This result was confirmed in 10 
patients with x26-positive response.
The x26-specific T-cell response of patient P26 was further characterized by intracellular staining of 
both IFN- and IL-10, to identify more precisely the T cells producing either or both cytokines. We 
found that 7.66% CD4+ T cells produced IFN- and 0.73 % produced IL-10 (Figure 4B, left and 
central panels) However, most CD4+ T cells activated by x26 (6.95% of total CD4+ T cells) produced 
IFN- but not IL-10 (Figure 4B, right panel). Less than 10% of the x26-specific CD4+ T-cell 
population (0.73% of total CD4+ T cells) produced IL-10 together with IFN-. No activated T cells 
producing IL-10 only were observed.
This is consistent with the small number of IL-10-producing T cells identified by Elispot and 
highlights the more precise quantification of IFN- and IL-10 by intracellular staining than by Elispot 
assays when these cytokines are produced simultaneously (compare Figures 3B and 4B).
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HLA class II restriction of x26 peptide
We used three experimental approaches to characterize the HLA class II-restriction of x26. After in 
vitro expansion, PBMC were incubated with anti-HLA-DR, anti-HLA-DQ or anti-HLA-DP antibodies 
and tested in Elispot assays. Prior incubation with anti-HLA-DR antibodies inhibited IFN--secretion 
upon stimulation with x26 by at least 80%. No such effect was observed after the prior incubation of 
PBMC with anti-HLA-DP or anti-HLA-DQ antibodies, or with irrelevant control anti-HLA-A2 
antibodies (Figure 5). The x26 epitope is therefore presented by HLA-DR molecules.
We assessed the capacity of x26 and of other pool C peptides to bind to various purified HLA-DR 
molecules. An HBcAg-derived peptide, c59-60, described as HBV promiscuous epitope (25) was 
tested in parallel (Table 1). High-affinity binding was observed for x25 peptide with at least 4 of the 
10 HLA-DR molecules tested (DRB1*0301, DRB1*1101, DRB1*1301 and DRB1*1501). The x26 
peptide could be presented by the HLA-DRB1*0101, HLA-DR01*0401, HLA-DRB1*1301 and HLA-
DRB5*0101 molecules. DRB1*1301 molecules could bind x22, x23 and x27 peptides as well, while 
x22 also bound to DRB4*0101. In comparison, the HBcAg-derived promiscuous epitope exhibited a 
good affinity for DRB1*0301, DRB1*1301 and DRB1*1501.
Finally, we genotyped the HLA-DR molecules of 30 inactive HBV carriers with or without x26-
specific T cells. For the HLA-DRB1 gene, the prevalence of alleles DRB1*0301 (9/30), 
DRB1*0401(9/30), DRB1*1101 (9/30) and DRB1*1301 (7/30) was high among the studied patients. 
In 16 patients, the presence or absence of HLA-DR alleles binding x26 (HLA-DRB1*0101, HLA-
DR01*0401, HLA-DRB1*1301 and HLA-DRB5*0101) was found to be related to specific IFN--
secreting T-cell reactivity (Table 2). 
Recognition of viral mutants by x26-specific T cells
Some HBx mutations in basic core promoter mutant viruses concern the x26 epitope. An analysis of 
sequences from 40 cloned HBV genomes published in GenBank (http://www.ncbi.nlm.nih.gov) shows 
that the frequent codon 130 and 131 (K130M and V131I) mutations were present in 12 of the 40 
sequences. Codon 127 (I127T) mutation occurred in 4 of the 40 HBx sequences.  We therefore 
evaluated the recognition of viral sequence variants by x26-specific T cells. For PBMC stimulation in 
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vitro, we used x26 peptide, covering the wild-type epitope, separately or mixed with the peptides V2 
and V3, corresponding to viral mutant sequences. No activation of x26-specific T cells by the variant 
peptides V2 and V3 was found in 10 of 13 patients with x26-specific T-cell responses (Figure 6). 
When the three peptides were used for in vitro expansion (Figure 6 right panel), markedly fewer cells 
were recalled in only three patients in Elispot assay with the variant peptides. None of 12 patients with 
x26-negative T-cell responses in IFN- Elispot assays had T-cell responses to variant peptides (not 
shown).
We investigated whether mutant peptides activated IL-10- rather than IFN--secreting T cells, by 
assessing cytokine secretion after the stimulation of PBMC with V2 and V3. No IL-10-secreting T 
cells were found in 15 studied patients with (n=6) or without (n=9) x26-specific IFN--secreting T 
cells. In conclusion, viral mutant sequences activated T cells specific for the x26 epitope much less 
efficiently and no cross-recognition of variant sequences by x26 specific-T cells was found.
Sequencing of HBV viral DNA from patients
We next investigate if HBV genome from patients may have viral mutations affecting the x26 epitope. 
Sequencing of the x26 encoding HBV DNA region could be performed only on three samples (P48, 
P59, P46) with HBV viral load exceeding 2x104 copies /ml and detectable HBV DNA after nested 
PCR (see online figure).  For patients P48 and P59, A-T and G-A mutations at nucleotides 1762 and 
1764 were found in HBV genome, changing amino acid in the HBx protein at positions K130M and 
V131I. Clinical data from patient P48 shows that this patient was infected at birth with an HBeAg-
negative mutant (see online Table). X26 T-cell response was found negative in this patient (see Table 
2). In contrast, in patient P59 carrying a virus with BCP mutation, x26-specific T cells were detected 
in PBMC taken at the time of DNA sequencing (Figure 2). Finally, the amplified virus from patient 
P46 with x26-specific T-cell response (Figure 2) showed a wild type BCP sequence. 
This indicates that HBV variants with BCP mutations can be found in some of our patients at the 
inactive carrier state of the disease. 
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DISCUSSION
HBV-specific CD4+ T cells play an important role in HBV infection, secreting the Th1 cytokines that 
downregulate HBV replication (27) and by contributing to the induction and maintenance of efficient 
CD8+ T-cell and B-cell responses (28). CD4+ T-cell epitopes have been identified in the core protein 
(25), HBe antigen (29), envelope (30) and polymerase proteins (31). Immune responses to HBx 
protein are poorly documented, with only one study dealing with CD4+ T-cell responses (20). In an 
attempt to define more accurately the breadth and epitope specificity of T-cell responses to HBx 
protein, we carried out a systematic analysis of T cells from 52 chronic HBV carriers. Following in 
vitro stimulation with pools of peptides covering the HBx sequence, IFN--secreting T cells specific 
for HBx were detected in 69% of patients, and in 67% (24/36) of them CD4+ T cells could be defined. 
This contrasts with the low prevalence of the Th cell responses against structural HBV proteins 
usually detected during chronic HBV infection. In this study, using the core 50-69 peptide (25, 32) for 
stimulation of PBMC and our cutured Elispot assay, IFN--secreting T-cell response was found in 3 
out of 8 patients, but with a ten fold lower number of specific T cells (data not shown). Previous 
studies have found that HLA-class II-restricted nucleocapsid antigen-specific Th cell responses are 
only detectable transiently during hepatitis exacerbation (14, 33). The CD4+ T-cell response to 
envelope proteins is markedly reduced during chronic HBV infection (1, 34). The high prevalence of 
IFN--secreting HBx-specific T cells reported here may be due to the protein itself or to the clinical 
status of the patients, i.e. HBV carriers in the inactive stage of the disease with less than 100,000 HBV 
copies/ml. The presence of HBx-specific CD4+ T cells during chronic infection may reflect T-cell 
activation due to the release of HBx protein by apoptotic hepatocytes during viral replication. The 
persistence of HBx-specific T cells could be related to the small amounts of HBx produced by infected 
hepatocytes, preventing the deletion or anergy of specific T cells occurring with other highly 
expressed viral antigens, such as HBsAg or HBcAg.  The impact of viral load on antiviral T-cell 
responses has been characterized in mouse models of chronic infection and in humans (35). T-cell 
responses to HBV antigens are detected more easily in patients with less than 107 copies/ml or after 
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successful antiviral treatment (36, 37). Consistent with these data, we found x26-specific T cells after 
stimulation of PBMC from only 1 of 13 patients with chronic active hepatitis and >105 copies/ml (data 
not shown). 
In contrast to the high prevalence of IFN--secreting HBx-specific T cells, IL-10-secreting T cells 
were detected in very few of the studied patients, always in the presence of IFN- production. This is 
consistent with previous reports of IL-12-induced IFN-/IL-10-secreting T cells generated in response 
to chronic infection (38, 39). Regulatory T cells specific for HBx, producing IL-10, are therefore 
unlikely to exist in our group of patients (40). This contrasts with HCV persistent infection, which is 
associated with enhanced IL-10 production in response to non-structural HCV antigens such as NS3, 
IL-10-producing T cells in the liver and weak CD4+ Th 1 reactivity in the periphery (16, 41).
We observed a high prevalence of peripheral CD4+ T-cell responses principally targeting the C-
terminal part of HBx. This finding is in agreement with a previous report characterizing T-cell clones 
recognizing peptides within this domain of HBx (20). Remarkably, most of our patients had IFN--
secreting CD4+ T cells recognizing a previously unidentified single peptide, HBx 126-140 referred 
here to x26. In addition, x26 peptide was immunogenic in the context of multiple HLA-class II 
molecules and may therefore be considered a promiscuous epitope. Nevertheless, some patients with 
x26-specific T cells lack the HLA-DR molecules that bound the peptide with high affinity in vitro. 
Other class II molecules not tested here are therefore probably able to bind x26. The partial correlation 
between the HLA-DR-restriction of the peptides and the pattern of DR alleles from different donors is 
consistent with published findings (31, 42).
Chronic HBV infection evolves from an initial HBeAg-positive phase, through HBe seroconversion to 
an HBeAg-negative phase in which replication levels are lower. This process is characterized by a 
progressive switch from viral quasi-species dominated by “wild-type” variants lacking precore or core 
promoter mutations, to viral quasi-species in which precore or core promoter variants predominate 
(43, 44). But it was recently shown that precore and core promoter mutations exist in a substantial 
proportion of patients before HBeAg clearance (22). What role do x26-specific IFN--secreting T cells 
play against both wild-type and mutated x26-derived sequences? The effector properties of x26-
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specific T cells may constitute an immune system pressure against which these mutant viral variants 
are selected.
The lack of recognition of variant HBx peptides, corresponding to BCP mutant sequences, by x26-
specfic T cells could not be explained by a decreased binding capacity of these sequences to HLA-DR 
molecules, as shown by comparative binding studies with the x26, V2 and V3 peptides and purified 
class II molecules (data not shown). Although core promoter mutations may appear early in HBV 
infection (8), the possibility of initial infection with the mutant virus cannot be excluded. This is the 
case for patient P48 who was infected at birth with an HBeAg-negative virus, and lacked for x26-
specific T-cell response. On the other hand, a wild-type sequence virus was found in patient P46 
concomitantly with detectable x26-specific T cells. However, for other patients such as P59 who were 
initially infected with a “wild-type” variant lacking core promoter mutations, x26-specific memory T 
cells may exist and can be detected in our assay despite the presence of a core promoter variant viral 
quasi-species at the time of blood collection. Our study shows that HBV strains with mutations 
affecting the immunodominant HBx epitope are likely to induce weaker T-cell responses, favoring the 
accumulation of such mutant strains.
Mutations resulting in HBx protein truncation have also been associated with low levels of HBV 
replication and decreases in hepatitis activity in anti-HBe antibody-positive HBV carriers (45). Thus, 
at least some of the studied chronic carriers may produce truncated HBx. The presence of BCP 
mutants or truncated HBx mutants might account for the lack of T-cell reactivity specific for the wild-
type x26 peptide in some of our patients. Therefore, x26 and variant peptides could be used for the 
immunomonitoring of HBV sequence changes during disease progression. This hypothesis should be 
tested in longitudinal studies in groups of patients differing in clinical status.
In addition, the immunogenicity, the promiscuous HLA-DR binding and the efficient activation of 
specific IFN--secreting T cells of this newly described HBx epitope suggest that it is a potential 
candidate for use in therapeutic vaccines for patients with chronic HBV infection.
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Legends to Figures
Figure 1. Presence and diversity of HBx-specific IFN--secreting T cells in 52 patients with chronic HBV 
infection. PBMCs were stimulated in vitro with HBx-derived 15-mer peptides covering the whole HBx 
sequence, divided into pools A, B and C. IFN--secreting T cells were determined by Elispot, using the same 
peptide pools. The proportion of patients testing positive is indicated on the top of each column. A) Percentage 
of patients with undetectable HBx-specific T cells (white column) and with HBx-specific T cells activated with 
each peptide pool (gray columns); B) diversity of recognition of regions within the HBx protein by HBx-specific 
T cells (gray striped columns).
Figure 2. IFN--secreting T cells upon stimulation with peptide pool C and mapping of the T-cell response to 
single peptides. Number of IFN--secreting T cells determined by Elispot and expressed as the number of 
specific spot-forming cells (SFC)/106 PBMCs after in vitro stimulation with peptide pool C (left panel), 
individual peptide x26 (middle panel), and single peptides or groups of peptides from pool C with the exception 
of x26 peptide (right panel). In the right panel, the number of SFC is indicated on each bar. The scale of the right 
panel differs from that of the left and central panels. ND: not done.
Figure 3. IFN-- and IL-10-secreting T cells determined by Elispot assays after in vitro stimulation of PBMC 
with the entire peptide pool C or x26 alone. Number of IFN-- or IL-10 spot-forming cells (SFC)/106 PBMC 
(black and gray columns, respectively) of 11 patients with only IFN--secreting T cells (A panel) and 7 patients 
with both IFN-- and IL-10-secreting T cells (B panel). Number of SFC is indicated on the top of each column. 
The cutoff points for Elispot assays are 62 IFN-- and 40 IL-10-SFC/106 PBMC.
Figure 4.  Phenotype of x26-specific T cells after in vitro expansion from PBMC with x26. A) Percentages of 
IFN--secreting CD3+ CD4+ (left panel) or CD3+ CD8+ (right panel) specific T cells are shown, B) within the 
CD4+ T-cell population, the percentages of x26-specific CD4+ T cells secreting IFN- (left panel), IL-10 
(central panel) and IL-10 and/or IFN- (right panel) are shown.
Figure 5.  Anti-MHC class II antibody-mediated inhibition of IFN- secretion by x26-specific T cells. PBMC 
expanded in vitro with peptide x26 were first incubated with anti-class II HLA antibodies — anti-HLA-DR, anti-
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HLA-DQ or anti-HLA-DP — or with an irrelevant antibody (anti-HLA-A2). PBMC were then tested in Elispot 
assays as described in Materials and Methods. Results obtained with three representative patients are shown.
Figure 6. Recognition of viral mutants by x26-specific T cells. PBMC from 13 patients with known x26-
specific IFN--producing T cells were expanded in vitro separately with x26 peptide (left panel) or with a 
mixture of x26, V2 and V3 peptides (right panel). IFN--secretion after the activation with each of the three 
peptides in Elispot assays is shown.
Figure online. Amino acid sequence of x26 region.
Legends to Tables
Table (available online). Clinical, virological and immunological characteristics of patients included in this 
study.
Table 1. Binding of HBx-derived peptides to immunopurified class II HLA molecules. Data are expressed as 
relative activity: ratio of the IC50 of the peptide to the IC50 of the reference peptide. The relative activities of pool 
C peptides and an HBcAg-derived peptide (c50-69) are shown. Boldface indicates relative binding affinity below 
100 and corresponds to good binders.
Table 2. Comparative analysis of patients’ HLA-DR genotypes, x26-binding HLA-DR molecules and x26-
specific IFN--secreting T-cell responses. Brackets for DRB1 genotype indicate that heterozygosity could not be 
confirmed with the current assay. (#) HLA-DR molecules binding x26, as shown in Table 1 for DRB1*0101, 
DRB1*0401, DRB1*1301 and DRB5*0101. (##) determined by Elispot assays and expressed as ranges of IFN-
-SFC per million PBMC: + 100-500; ++ 500-1000; +++ 1000-2000 and ++++ >2000.
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